BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21209397)

  • 61. Effect of prebiotics on biomarkers of colorectal cancer in humans: a systematic review.
    Clark MJ; Robien K; Slavin JL
    Nutr Rev; 2012 Aug; 70(8):436-43. PubMed ID: 22835137
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Effect of intensive treatment with atorvastatin versus standard doses of statins on the risk of stroke. A meta-analysis from five randomized trials including 25,709 patients].
    Fernándezde Bobadilla J; Moreno R; Fernández C; Martínez A; Sánchez-Maestre C; Ezpeleta-Echevarri D
    Rev Neurol; 2009 Jun 1-15; 48(11):561-5. PubMed ID: 19472152
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
    Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis.
    Paul F; Waiczies S; Wuerfel J; Bellmann-Strobl J; Dörr J; Waiczies H; Haertle M; Wernecke KD; Volk HD; Aktas O; Zipp F
    PLoS One; 2008 Apr; 3(4):e1928. PubMed ID: 18398457
    [TBL] [Abstract][Full Text] [Related]  

  • 65. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 66. High-dose atorvastatin after stroke or transient ischemic attack.
    Amarenco P; Bogousslavsky J; Callahan A; Goldstein LB; Hennerici M; Rudolph AE; Sillesen H; Simunovic L; Szarek M; Welch KM; Zivin JA;
    N Engl J Med; 2006 Aug; 355(6):549-59. PubMed ID: 16899775
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia.
    van Wissen S; Smilde TJ; Trip MD; de Boo T; Kastelein JJ; Stalenhoef AF
    Heart; 2003 Aug; 89(8):893-6. PubMed ID: 12860867
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
    Lee CW; Kang SJ; Ahn JM; Song HG; Lee JY; Kim WJ; Park DW; Lee SW; Kim YH; Park SW; Park SJ
    Am J Cardiol; 2012 Jun; 109(12):1700-4. PubMed ID: 22440123
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
    Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Atorvastatin-induced modulation of monocyte respiratory burst in vivo in patients with IgA nephropathy: a chronic inflammatory kidney disease.
    Lundberg S; Lundahl J; Gunnarsson I; Jacobson SH
    Clin Nephrol; 2010 Mar; 73(3):221-8. PubMed ID: 20178722
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Effectiveness of atorvastatin compared to other statins of usual clinical practice in primary care].
    Sicras Mainar A; Navarro Artieda R; Fernández de Bobadilla J; Checa JC
    Med Clin (Barc); 2006 Oct; 127(14):555-6. PubMed ID: 17145005
    [No Abstract]   [Full Text] [Related]  

  • 73. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparing the effects of COX and non-COX-inhibiting NSAIDs on enhancement of apoptosis and inhibition of aberrant crypt foci formation in a rat colorectal cancer model.
    Martin JE; Young GP; LE Leu RK; Hu Y
    Anticancer Res; 2013 Sep; 33(9):3581-8. PubMed ID: 24023283
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators.
    Wanner C; Krane V; Ruf G; März W; Ritz E
    Kidney Int Suppl; 1999 Jul; 71():S222-6. PubMed ID: 10412782
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
    Hilleman DE; Wurdeman RL; Lenz TL
    Pharmacotherapy; 2001 Apr; 21(4):410-5. PubMed ID: 11310513
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 78. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
    Smith DG; McBurney CR
    Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
    Shioji K; Izuhara M; Mitsuoka H; Uegaito T; Matsuda M;
    Cardiovasc Ther; 2014 Jun; 32(3):97-104. PubMed ID: 24456217
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Atorvastatin and fibrinogen--a small subgroup shows extreme response.
    Sinzinger H; Rodrigues M
    Atherosclerosis; 1999 Aug; 145(2):415-7. PubMed ID: 10488971
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.